News
-
-
PRESS RELEASE
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
NanoViricides receives regulatory approval to begin Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebola, leading to urgent need for effective antiviral drugs in DRC outbreak -
-
PRESS RELEASE
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NanoViricides, Inc. eagerly awaits approval for Phase II Clinical Trial of NV-387 Oral Gummies to treat Bundibugyo Ebolavirus in DRC. Financing secured for trial against fast-spreading Ebola outbreak -
-
PRESS RELEASE
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
NanoViricides, Inc. announces entering into securities purchase agreement for $3.8 million with institutional investor. Offering to be closed on July 27, 2026. Company offers broad-spectrum antivirals based on nanomedicine technology -
-
PRESS RELEASE
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
NanoViricides, Inc. applies for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DRC, aiming to combat Ebola outbreak with revolutionary antiviral drug -
-
PRESS RELEASE
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
NanoViricides announces National Ethics Committee approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebola; focusing on broad-spectrum antiviral treatment for pandemics
